Are Anti-SARS-CoV-2 Monoclonal Antibodies Beneficial for Outpatients with COVID-19?

For reducing viral load, a combination of two anti-SARS-CoV-2 monoclonal antibodies was only marginally better than placebo.

The anti–SARS-CoV-2 monoclonal antibody (mAb) bamlanivimab received emergency use authorization based on interim results of an industry-funded study (BLAZE-1; NEJM JW Infect Dis Jan 2021 and N Engl J Med 2020 Oct 28; [e-pub]) in which 577 outpatients (mean age, 45) with mild to moderate COVID-19 (67% with at least 1 risk factor for severe COVID-19) were randomized to receive a single infusion of placebo, one of three doses of bamlanivimab (700 mg, 2800 mg, or 7000 mg), or a combination of 2800 mg bamlanivimab plus 2800 mg etesevimab (a neutralizing anti–SARS-CoV-2 mAb that targets an epitope on the spike protein distinct from that of bamlanivimab). Change from baseline in log viral load (the primary outcome) was assessed at treatment day 11…

Reviewing Author

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Are Anti-SARS-CoV-2 Monoclonal Antibodies Beneficial for Outpatients with COVID-19?

Topics

Reviewing Author